Study S002575

A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

ClinicalTrials.gov record

Registration

Registration: NCT06851858
Acronym: ARAY
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 69
Start: 2025-03-12
Primary completion: 2026-05-26
Lead sponsor: AstraZeneca
Conditions: Endocrinology; Diabetes, Type II; Obesity
Interventions: DRUG:AZD6234; DRUG:Placebo to match
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Percent change in body weight from baseline at Study Week 26 [From baseline to week 26]
Weight loss ≥ 5% from baseline at Study Week 26 [From baseline to week 26]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.